Menu
Search
|

Menu

Close
X

Vertex Pharmaceuticals Inc VRTX.OQ (NASDAQ Stock Exchange Global Select Market)

177.40 USD
-- (--)
As of Jul 21
chart
Previous Close 177.40
Open --
Volume --
3m Avg Volume 574,096
Today’s High --
Today’s Low --
52 Week High 183.36
52 Week Low 136.78
Shares Outstanding (mil) 252.12
Market Capitalization (mil) 39,103.64
Forward P/E 150.12
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 23 analysts

KEY STATS

Revenue (mm, USD)
FY18
641
FY17
2,489
FY16
1,702
FY15
1,032
EPS (USD)
FY18
0.813
FY17
1.048
FY16
-0.459
FY15
-2.310
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
150.12
32.76
Price to Sales (TTM)
vs sector
18.35
5.73
Price to Book (MRQ)
vs sector
23.27
5.47
Price to Cash Flow (TTM)
vs sector
118.96
23.29
Total Debt to Equity (MRQ)
vs sector
34.02
16.84
LT Debt to Equity (MRQ)
vs sector
32.93
12.51
Return on Investment (TTM)
vs sector
12.80
14.61
Return on Equity (TTM)
vs sector
19.56
16.34

EXECUTIVE LEADERSHIP

Jeffrey Leiden
Chairman of the Board, President, Chief Executive Officer, Since 2012
Salary: $1,300,000.00
Bonus: --
Thomas Graney
Chief Financial Officer, Senior Vice President, Since 2017
Salary: $154,423.00
Bonus: $150,000.00
Ian Smith
Chief Operating Officer, Executive Vice President, Since 2017
Salary: $848,077.00
Bonus: --
Michael Parini
Executive Vice President, Chief Legal and Administrative Officer, Since 2017
Salary: $694,519.00
Bonus: --
David Altshuler
Executive Vice President - Global Research, Chief Scientific Officer, Since 2015
Salary: $596,731.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

50 Northern Ave
BOSTON   MA   02210-1862

Phone: +1617.3416393

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

SPONSORED STORIES